[go: up one dir, main page]

CO2024011221A2 - Compuestos y su uso en el tratamiento del cáncer - Google Patents

Compuestos y su uso en el tratamiento del cáncer

Info

Publication number
CO2024011221A2
CO2024011221A2 CONC2024/0011221A CO2024011221A CO2024011221A2 CO 2024011221 A2 CO2024011221 A2 CO 2024011221A2 CO 2024011221 A CO2024011221 A CO 2024011221A CO 2024011221 A2 CO2024011221 A2 CO 2024011221A2
Authority
CO
Colombia
Prior art keywords
compounds
cancer treatment
treatment
formula
pharmaceutically acceptable
Prior art date
Application number
CONC2024/0011221A
Other languages
English (en)
Inventor
Martin John Packer
Coura Rosalie Diene
Charlene Fallan
Sharanjeet Kaur Bagal
James Scott
Doyle Joseph Cassar
Johannes Wilhelmus Maria Nissink
Lakshmaiah Gingipalli
Sameer Pralhad Kawatkar
Qing Ye
Peter Astles
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO2024011221A2 publication Critical patent/CO2024011221A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Los compuestos de Fórmula (I) o una sal farmacéuticamente aceptable de los mismos son compuestos PROTAC útiles en el tratamiento del cáncer de próstata
CONC2024/0011221A 2022-01-21 2024-08-20 Compuestos y su uso en el tratamiento del cáncer CO2024011221A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263266982P 2022-01-21 2022-01-21
PCT/EP2023/051344 WO2023139199A1 (en) 2022-01-21 2023-01-20 Compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
CO2024011221A2 true CO2024011221A2 (es) 2024-08-30

Family

ID=85157086

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0011221A CO2024011221A2 (es) 2022-01-21 2024-08-20 Compuestos y su uso en el tratamiento del cáncer

Country Status (18)

Country Link
EP (1) EP4466260A1 (es)
JP (1) JP2025502985A (es)
KR (1) KR20240137054A (es)
CN (1) CN118574821A (es)
AR (1) AR128314A1 (es)
AU (1) AU2023209575A1 (es)
CA (1) CA3247485A1 (es)
CL (1) CL2024002154A1 (es)
CO (1) CO2024011221A2 (es)
CR (1) CR20240348A (es)
DO (1) DOP2024000137A (es)
IL (1) IL314316A (es)
MX (1) MX2024009018A (es)
PE (1) PE20241893A1 (es)
TW (1) TW202346281A (es)
UY (1) UY40123A (es)
WO (1) WO2023139199A1 (es)
ZA (1) ZA202406390B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024102810A1 (en) * 2022-11-08 2024-05-16 Montelino Therapeutics, Inc. Bi-functional compounds and methods for targeted ubiquitination of androgen receptor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3038979A1 (en) 2016-10-11 2018-04-19 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
JP7297053B2 (ja) * 2018-08-20 2023-06-23 アルビナス・オペレーションズ・インコーポレイテッド 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
WO2021231927A1 (en) * 2020-05-14 2021-11-18 The Regents Of The University Of Michigan Androgen receptor protein degraders with a tricyclic cereblon ligand
US20230257365A1 (en) * 2020-07-10 2023-08-17 The Regents Of The University Of Michigan Small molecule androgen receptor protein degraders

Also Published As

Publication number Publication date
JP2025502985A (ja) 2025-01-30
UY40123A (es) 2023-08-15
TW202346281A (zh) 2023-12-01
AU2023209575A1 (en) 2024-08-29
IL314316A (en) 2024-09-01
WO2023139199A1 (en) 2023-07-27
KR20240137054A (ko) 2024-09-19
PE20241893A1 (es) 2024-09-19
CA3247485A1 (en) 2023-07-27
MX2024009018A (es) 2024-08-06
CR20240348A (es) 2024-09-17
ZA202406390B (en) 2025-05-28
CL2024002154A1 (es) 2024-12-20
DOP2024000137A (es) 2024-08-30
CN118574821A (zh) 2024-08-30
AR128314A1 (es) 2024-04-17
EP4466260A1 (en) 2024-11-27

Similar Documents

Publication Publication Date Title
CO2024011199A2 (es) Composiciones y métodos para inhibir el factor b del complemento
DOP2022000117A (es) Inhibidores de kras g12c
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
UY29938A1 (es) Derivados de pirido-, pirazo- y pirimido-pirimidina y su uso como inhibidores de mtor
CL2024002805A1 (es) Compuestos derivados de dimetilpiperazin indazol sulfonamida como inhibidores de parg y uso para tratar cáncer.
CL2022003039A1 (es) Inhibidores de il4i1 y métodos de uso.
MX2023000418A (es) Fluorofenil beta-hidroxietilaminas y su uso en el tratamiento de la hiperglucemia.
CL2023003965A1 (es) Inhibidores cdk2.
MX2021010321A (es) Compuestos macrociclicos.
MX2023011715A (es) Compuestos de oxoisoindolina sustituidos con piridinilo.
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
MX2019009266A (es) Piridinas sustituidas con hidrocarbilsulfonilo y su uso en el tratamiento del cancer.
MX2019009354A (es) Piridinas sustituidas con heterociclilsulfonilo y su uso en el tratamiento del cancer.
CO2024011221A2 (es) Compuestos y su uso en el tratamiento del cáncer
MX392000B (es) Piridinas sustituidas con heteroarilsulfonilo y su uso en el tratamiento del cáncer.
CO2020010306A2 (es) Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado.
MX2025006661A (es) Inhibidores de polq
AR133028A1 (es) Composición farmacéutica que comprende un degradador de todas las kras
MX2022016406A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib.
AR128711A1 (es) Métodos para tratar carcinoma microcítico de pulmón
AR125479A1 (es) Inhibidores de il4i1 y métodos de uso
CL2025000383A1 (es) Combinaciones antineoplásicas que comprenden tratamiento dirigido.
CO2025002789A2 (es) Combinaciones de agentes antineoplásicos que comprenden un compuesto bifuncional con actividad inhibitoria de kras mutante g12d
CL2022000045A1 (es) Derivados de camptotecina con un resto disulfuro y un resto piperazina.
MX2025002228A (es) Metodos para el tratamiento o la profilaxis de la endometriosis